STANDARD BIOTOOLS Sells SOMALOGIC to ILLUMINA

Summary

Standard Biotools, enters transformation by strategically selling Somalogic to Illumina in a deal valued at up to $425 million, with an upfront cash payment of $350 million. Benzinga+ 2

Impact Analysis

The event is primarily at the company level, affecting Illumina, Standard Biotools, and Somalogic. The acquisition of Somalogic by Illumina involves a $350 million upfront payment with potential milestone payments up to $75 million. First-order effects include Illumina’s bolstered position in the proteomics sector, leveraging Somalogic’s data-driven technology. Immediate market reactions may involve stock price movements for Illumina (NASDAQ: ILMN) and Standard Biotools (NASDAQ: LAB). Second-order effects could include increased competition in the proteomics field, influencing related companies and potential advances in proteomics research and development. Investment opportunities may arise for investors interested in Illumina or the broader proteomics industry, including sector ETFs focusing on biotechnology. Risks include integration challenges and potential changes in market dynamics. Benzinga+ 3